XML 45 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Long-Term Investments (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Long-Term Investments [Abstract]    
Schedule of ownership percentages of investee
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2023   2022   treatments
Braingenesis Biotechnology Co., Ltd.   0.22%   0.22%  Cost Method
Genepharm Biotech Corporation   0.92%   0.92%  Cost Method
BioHopeKing Corporation   8.03%   8.03%  Cost Method
BioFirst Corporation   21.77%   21.77%  Equity Method
Rgene Corporation   28.85%   28.85%  Equity Method
   Ownership percentage    
   December 31,   December 31,   Accounting
Name of related party  2022   2021   treatments
Braingenesis Biotechnology Co., Ltd.   0.22%   0.22%  Cost Method
Genepharm Biotech Corporation   0.92%   0.92%  Cost Method
BioHopeKing Corporation   8.03%   8.03%  Cost Method
BioFirst Corporation   21.77%   21.77%  Equity Method
Rgene Corporation   28.85%   28.85%  Equity Method
Schedule of extent the investee relies
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

 
Name of related party   The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.   No specific business relationship
Genepharm Biotech Corporation   No specific business relationship
BioHopeKing Corporation   Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation   Loaned from the investee and provides research and development support service
Rgene Corporation   Collaborating with the Company to develop and commercialize drugs

  
Schedule of long-term investment
   March 31,
2023		   December 31,
2022		 
   (Unaudited)     
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,235   $7,169 
Genepharm Biotech Corporation   22,089    21,887 
BioHopeKing Corporation   820,519    813,014 
Sub total   849,843    842,070 
Equity Method Investments, net          
BioFirst Corporation   
-
    
-
 
Rgene Corporation   
-
    
-
 
Total  $849,843   $842,070 
   December 31,
2022		   December 31,
2021		 
Non-marketable Cost Method Investments, net        
Braingenesis Biotechnology Co., Ltd.  $7,169   $7,941 
Genepharm Biotech Corporation   21,887    24,244 
BioHopeKing Corporation   813,014    900,570 
Subtotal   842,070    932,755 
Equity Method Investments, net          
BioFirst Corporation   
-
    
-
 
Rgene Corporation   
-
    
-
 
Total  $842,070   $932,755 
Schedule of balance sheet
   March 31,
2023		   December 31,
2022		 
   (Unaudited)     
Current Assets  $1,958,500   $1,543,152 
Non-current Assets   801,410    739,472 
Current Liabilities   1,675,194    2,663,051 
Non-current Liabilities   357,150    103,447 
Stockholders’ Equity (Deficit)   727,566    (483,874)
   March 31,
2023		   December 31,
2022		 
   (Unaudited)     
Current Assets  $54,987   $68,302 
Noncurrent Assets   288,160    303,893 
Current Liabilities   2,491,974    2,478,868 
Noncurrent Liabilities   2,048    2,441 
Shareholders’ Deficit   (2,150,875)   (2,109,114)
   December 31,
2022		   December 31,
2021		 
Current Assets  $1,543,151   $2,205,669 
Noncurrent Assets   739,472    959,454 
Current Liabilities   2,663,051    2,909,703 
Noncurrent Liabilities   103,447    32,522 
Stockholders’ Equity   483,874    222,898 
   December 31,
2022		   December 31,
2021		 
Current Assets  $68,302   $73,452 
Noncurrent Assets   303,893    374,423 
Current Liabilities   2,478,868    1,934,786 
Noncurrent Liabilities   2,441    
-
 
Shareholders’ Deficit   (2,481,309)   (1,486,911)
Schedule of statement of operation
   Three months Ended
March 31,		 
   2023   2022 
   (Unaudited) 
Net sales  $
-
   $8,808 
Gross profit   
-
    6,133 
Net loss   (406,233)   (498,940)
Share of losses from investments accounted for using the equity method   
-
    
 
 

 

   Three months Ended
March 31,		 
   2023   2022 
   (Unaudited) 
Net sales  $
-
   $
-
 
Gross Profit   
-
    
-
 
Net loss   (81,842)   (149,480)
Share of loss from investments accounted for using the equity method   
-
    
-
 
   Year Ended
December 31,		 
   2022   2021 
Net sales  $30,162   $26,693 
Gross profit   8,239    8,348 
Net loss   (1,274,539)   (2,276,892)
Share of losses from investments accounted for using the equity method   
-
    (269,844)

 

   Year Ended
December 31,		 
   2022   2021 
Net sales  $
   -
   $
-
 
Gross Profit   
-
    
-
 
Net loss   (1,550,123)   (576,514)
Share of loss from investments accounted for using the equity method   
-
    
-
 
Schedule of equity investments
    Three months Ended
March 31,		 
    2023    2022 
    (Unaudited) 
Share of equity method investee losses  $
     -
   $
     -
 
   Year Ended
December 31,		 
   2022   2021 
Share of equity method investee losses  $
      -
   $(269,844)